Glenmark Pharmaceuticals Ltd (GLENMARK) is currently trading at 2,183.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Glenmark Pharmaceuticals is an integrated global pharmaceutical company focused on discovery, development, manufacturing and commercialization of prescription medicines, generics and APIs, with R&D in NCEs and NBEs and manufacturing facilities across India, the US, Europe, Latin America and Switzerland that serve both regulated and emerging markets. Glenmark has pivoted materially toward innovation and biologics: it launched a biosimilar of liraglutide in India, built antibody manufacturing capabilities in Switzerland, and formed Ichnos Glenmark Innovation to accelerate oncology drug development, indicating Glenmark is transitioning from a pure generics player to a hybrid innovator and branded-biologics company. The company has been actively optimizing its portfolio through strategic deals and divestments, including the FY24 75% sale of Glenmark Life Sciences to Nirma and earlier divestments like the VWash franchise, showing Glenmark is redeploying capital from commodity API assets into higher-margin branded, biosimilar and specialty franchises. Glenmark’s global commercialization strength remains a competitive asset: it has an expanding branded generics and specialty product roster including Ryaltris commercialized in over 44 markets, direct distribution start in the U.S. for Ryaltris in 2026, and a large authorized generic portfolio in the U.S. which together provide multi-geography revenue channels. Manufacturing and regulatory investments are central to Glenmark’s strategy, demonstrated by the substantial Monroe, North Carolina facility investment, multiple ANDA approvals and newly operational modules at Ankleshwar, which collectively improve production scale, regulatory supply reliability, and the company’s ability to support complex generic launches and specialty product rollouts.

Over the past 52 weeks, Glenmark Pharmaceuticals Ltd has traded between a low of ₹1,794.00 and a high of ₹2,536.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Glenmark Pharmaceuticals Ltd has a market capitalization of approximately 62,230.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Glenmark Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 62,230.54 Cr, Glenmark Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Glenmark Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd is 34.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved Glenmark’s unaudited results in a meeting held on July 31, 2026, for the quarter ended June 30, 2026.

Glenmark Pharmaceuticals has declared an interim dividend of ₹2.50 per equity share (face value Re 1) for FY2025-26.

Glenmark 3.0 is the company’s strategy to move up the value chain toward an innovation-led model, while scaling branded products and maintaining a large commercial footprint.

Glenmark, via Glenmark Specialty S.A., signed an exclusive license and collaboration agreement with Hengrui for Trastuzumab Rezetecan, with $18 million upfront and up to $1,093 million in milestones plus royalties.